Kamal A Saeed

Array ( [id] => 20219791 [patent_doc_number] => 20250282722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-11 [patent_title] => 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME [patent_app_type] => utility [patent_app_number] => 19/215938 [patent_app_country] => US [patent_app_date] => 2025-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79859 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19215938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19909227 [patent_doc_number] => 12285412 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-04-29 [patent_title] => Organoselenium benzimidazole compounds for treating cancer [patent_app_type] => utility [patent_app_number] => 19/003381 [patent_app_country] => US [patent_app_date] => 2024-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 5841 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19003381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20049821 [patent_doc_number] => 20250188043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-12 [patent_title] => LEFLUTROZOLE COMPOSITIONS OF MATTER AND PROCESSES FOR PREPARATION [patent_app_type] => utility [patent_app_number] => 18/973849 [patent_app_country] => US [patent_app_date] => 2024-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26909 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18973849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19846640 [patent_doc_number] => 20250091991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION [patent_app_type] => utility [patent_app_number] => 18/968441 [patent_app_country] => US [patent_app_date] => 2024-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 83692 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18968441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19666086 [patent_doc_number] => 12178806 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-12-31 [patent_title] => Method for contacting cancer cells with antitumor agent and apoptotic inducer [patent_app_type] => utility [patent_app_number] => 18/799676 [patent_app_country] => US [patent_app_date] => 2024-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 7512 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18799676 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19743897 [patent_doc_number] => 20250032462 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => BAX ACTIVATORS AND USES THEREOF IN CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 18/752081 [patent_app_country] => US [patent_app_date] => 2024-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18625 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18752081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19496408 [patent_doc_number] => 20240335426 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA [patent_app_type] => utility [patent_app_number] => 18/748709 [patent_app_country] => US [patent_app_date] => 2024-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8689 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18748709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20201481 [patent_doc_number] => 12404250 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-02 [patent_title] => PARP inhibitors for treating cancer and asthma [patent_app_type] => utility [patent_app_number] => 18/745664 [patent_app_country] => US [patent_app_date] => 2024-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 8 [patent_no_of_words] => 8028 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 154 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18745664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19897798 [patent_doc_number] => 12275701 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-15 [patent_title] => Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators [patent_app_type] => utility [patent_app_number] => 18/741888 [patent_app_country] => US [patent_app_date] => 2024-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79907 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 272 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18741888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19876856 [patent_doc_number] => 20250109113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-03 [patent_title] => CFTR REGULATORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/731154 [patent_app_country] => US [patent_app_date] => 2024-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71753 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18731154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19897819 [patent_doc_number] => 12275724 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-15 [patent_title] => Processes and intermediates for the preparation of soluble guanylate cyclase stimulators [patent_app_type] => utility [patent_app_number] => 18/671182 [patent_app_country] => US [patent_app_date] => 2024-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 42831 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18671182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19503750 [patent_doc_number] => 12115148 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-10-15 [patent_title] => 3-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-5-(2-hydroxy-5-nitrobenzylidene)thiazolidine-2,4-dione as a potential antitumor and apoptotic inducer [patent_app_type] => utility [patent_app_number] => 18/661337 [patent_app_country] => US [patent_app_date] => 2024-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 7486 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18661337 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20302409 [patent_doc_number] => 12448387 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yljimidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide [patent_app_type] => utility [patent_app_number] => 18/659338 [patent_app_country] => US [patent_app_date] => 2024-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 37160 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18659338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19599453 [patent_doc_number] => 20240390333 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/656222 [patent_app_country] => US [patent_app_date] => 2024-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18656222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19977138 [patent_doc_number] => 12344599 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-01 [patent_title] => Prodigiosin analogs and methods of use [patent_app_type] => utility [patent_app_number] => 18/636634 [patent_app_country] => US [patent_app_date] => 2024-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 129 [patent_figures_cnt] => 137 [patent_no_of_words] => 17967 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18636634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379248 [patent_doc_number] => 20240269118 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => PROCESSES FOR PREPARING SOLID STATE FORMS [patent_app_type] => utility [patent_app_number] => 18/622657 [patent_app_country] => US [patent_app_date] => 2024-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13130 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18622657 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19543070 [patent_doc_number] => 20240360106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/605379 [patent_app_country] => US [patent_app_date] => 2024-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60297 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18605379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19571758 [patent_doc_number] => 20240376050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => SUBSTITUTED PYRROLIDONES AND PIPERIDONES AS SMALL MOLECULE INHIBITORS OF EZH2 AND EED PROTEIN BINDING [patent_app_type] => utility [patent_app_number] => 18/594979 [patent_app_country] => US [patent_app_date] => 2024-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10015 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18594979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19210660 [patent_doc_number] => 11999708 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-06-04 [patent_title] => Thiazole tethered organoselenides as 5-lipoxygenase inhibitors [patent_app_type] => utility [patent_app_number] => 18/590133 [patent_app_country] => US [patent_app_date] => 2024-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4468 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18590133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19510465 [patent_doc_number] => 20240342151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => DEUTERATED COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION [patent_app_type] => utility [patent_app_number] => 18/582046 [patent_app_country] => US [patent_app_date] => 2024-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28538 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18582046 [rel_patent_id] =>[rel_patent_doc_number] =>)